At an 11-Year Low with a 4.9% Dividend Yield, Is This Value Stock a No-Brainer Buy for Passive Income in 2026?
Jan 11, 2026 by Adria CiminoIt's Official: Warren Buffett Has Retired. But Here Are 3 Ways to Continue Benefiting From His Investing Wisdom in 2026.Buffett isn't completely disappearing from the investing scene.
Jan 11, 2026 by Patrick SandersSoundHound AI: Buy or Sell in 2026?SoundHound continues to post losses, but that's because it is funding some ambitious plans.
Jan 11, 2026 by James Brumley3 REITs Every Investor Should Know AboutThis may be the right time to add something completely different to your portfolio.
Jan 11, 2026 by Will Ebiefung2 Reasons to Buy Amazon Stock in 2026This technology giant has plenty of room for growth.
Jan 11, 2026 by Eric VolkmanWhy StubHub Stock Popped by 15% Last MonthThe company was making very assertive moves to expand its business into different entertainment niches.
Jan 11, 2026 by Eric VolkmanWhy Investors Froze out Lennar Stock in DecemberWorrying about the state of the home construction industry in the U.S. was reasonable, but the company didn't deserve the big sell-off it suffered.
Jan 11, 2026 by Jonathan PoncianoWhat This Insider Trim at AnaptysBio Means for Investors After a 260% Stock RallyThis biotech innovator in antibody therapies just reported a significant insider sale amid a period of strong share price gains.
Jan 11, 2026 by Adria CiminoIt's Official: Warren Buffett Has Retired. But Here Are 3 Ways to Continue Benefiting From His Investing Wisdom in 2026.Buffett isn't completely disappearing from the investing scene.
Jan 11, 2026 by Katie BrockmanSCHG vs. MGK: Are Investors Better Off With Diversified Tech Exposure or a Mega-Cap ETF?Explore how differences in cost, holdings, and risk profiles set these two popular growth ETFs apart for investors.
Jan 11, 2026 by Keith NoonanIf You'd Invested $100 in Nvidia 10 Years Ago, Here's How Much You'd Have TodayNvidia stock has made fortunes for patient investors.
Jan 11, 2026 by Patrick SandersSoundHound AI: Buy or Sell in 2026?SoundHound continues to post losses, but that's because it is funding some ambitious plans.
Jan 11, 2026 by Alex CarchidiPrediction: XRP Will Hit $3 in 2026Don't hold your breath for new all-time highs this year.
Jan 11, 2026 by James Brumley3 REITs Every Investor Should Know AboutThis may be the right time to add something completely different to your portfolio.
Jan 11, 2026 by Adam SpataccoIs Archer Aviation's Deal With Nvidia a Game Changer?Archer Aviation recently announced it is collaborating with Nvidia for its next-generation aviation systems.
Jan 11, 2026 by James HiresArtificial Intelligence (AI) Is Driving a New Wave of Infrastructure Spending. This Stock Is Key.This AI infrastructure company provides an overlooked but critical resource to data centers, and is set for a growth spurt because of it.
Jan 11, 2026 by Geoffrey SeilerShould You Forget Nvidia and Buy These 2 Artificial Intelligence (AI) Stocks Right Now?The stocks of Broadcom and AMD could have higher upside than Nvidia in the coming years.
Jan 11, 2026 by Reuben Gregg BrewerShould You Buy NuScale Power Stock While It's Below $24?NuScale Power's stock has lost more than half its value. Is this an opportunity or an indication of risk?
Jan 11, 2026 by Jonathan PoncianoWhat Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock RunThis clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance.
Jan 11, 2026 by Geoffrey SeilerApplied Digital Shares Surge on Bright Outlook. Is It Too Late to Buy the Stock?The stock has been a huge winner over the past year.
Jan 11, 2026 by John Ballard2 Dominant Tech Stocks to Buy in January and Hold for 5 YearsThese stocks are poised for substantial growth.
Jan 11, 2026 by Maurie BackmanThis Could Be the Biggest 401(k) Mistake You Make in 2026Don't set yourself up for failure.
Jan 11, 2026 by Jonathan PoncianoCorcept Insider Transaction Explained After Shares Tumble 50% in One DayFocused on therapies for endocrine and oncologic conditions, this biotech reported significant insider selling in its latest SEC filing.
